The company is moving quickly to bring its antibody oligonucleotide conjugates to patients in three separate muscular dystrophy diseases, causing unease for its rivals.
Avidity Biosciences could be about to transform treatment of three muscular dystrophy diseases with first-in-class RNA-based therapies, the most advanced being on track for filing by the end of 2025.
The San Diego, CA-based firm is developing a new hybrid drug class called antibody oligonucleotide conjugates (AOCs), which use monoclonal...
A new small-molecule approach to turning on beneficial genes to counteract disease-causing mutations is being pioneered by Insmed’s UK-based scientists.
As AI-driven firms like Insilico, big pharma like J&J, Amgen, GSK and AstraZeneca and Chinese and Indian firms like BeOne and Dr. Reddy’s respectively advance PRMT5 inhibitor candidates, what’s driving interest, what could lead to the first global approval and what are the challenges ahead?
Analysts see the new strategy as a way to address pressure from the Trump administration’s most favored nation drug pricing proposals.
